Literature DB >> 10447029

Cellular and acellular pertussis vaccines in adults.

W A Keitel1.   

Abstract

Immunization against pertussis after childhood previously was considered unnecessary, because severe illness and complications rarely developed in older persons. The rising incidence of pertussis among older adolescents and adults and the transmission of infection from adults to infants suggest that booster immunization may be necessary to more effectively control pertussis in all age groups. Whole cell pertussis vaccines are regarded as unsuitable for routine use in adults because of reports of frequent moderate to severe reactogenicity at the injection site and occasional systemic reactions. The introduction of safe and effective acellular pertussis vaccines provides us with an opportunity to reconsider booster immunization of adolescents and adults. Several vaccines containing purified component(s) of Bordetella pertussis have been well tolerated and highly immunogenic when given to healthy adults. A clear understanding of the impact of pertussis in adolescents and adults will help to define the need for booster immunization after childhood.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447029     DOI: 10.1086/515064

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  CD4(+) CD25(+) T cells prevent arthritis associated with Borrelia vaccination and infection.

Authors:  Dean T Nardelli; Joseph P Cloute; K H Kevin Luk; Jose Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

3.  Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production.

Authors:  Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

5.  Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody.

Authors:  Dean T Nardelli; Matthew A Burchill; Douglas M England; Jose Torrealba; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

6.  Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Authors:  Nicholas J Kotloski; Dean T Nardelli; Sara Heil Peterson; Jose R Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

7.  Progress in the Diagnosis, Prevention, and Treatment of Pertussis.

Authors:  Flor M. Munoz; Wendy A. Keitel
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

8.  Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.

Authors:  Sara Heil Peterson; Dean T Nardelli; Thomas F Warner; Steven M Callister; Jose R Torrealba; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

9.  Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Corey A Amlong; Dean T Nardelli; Sara Heil Peterson; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  The Burden of Pertussis Hospitalization in HIV-Exposed and HIV-Unexposed South African Infants.

Authors:  Nasiha Soofie; Marta C Nunes; Prudence Kgagudi; Nadia van Niekerk; Tselane Makgobo; Yasmeen Agosti; Cleopas Hwinya; Jayani Pathirana; Shabir A Madhi
Journal:  Clin Infect Dis       Date:  2016-12-01       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.